U
345.09
2.63 (0.77%)
| Penutupan Terdahulu | 342.46 |
| Buka | 348.10 |
| Jumlah Dagangan | 114,286 |
| Purata Dagangan (3B) | 517,930 |
| Modal Pasaran | 15,353,245,696 |
| Harga / Pendapatan (P/E TTM) | 15.87 |
| Harga / Pendapatan (P/E Ke hadapan) | 12.99 |
| Harga / Jualan (P/S) | 6.43 |
| Harga / Buku (P/B) | 2.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2024 - 4 Nov 2024 |
| Margin Keuntungan | 40.31% |
| Margin Operasi (TTM) | 54.51% |
| EPS Cair (TTM) | 22.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 15.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.56% |
| Nisbah Semasa (MRQ) | 4.58 |
| Aliran Tunai Operasi (OCF TTM) | 1.14 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 710.09 M |
| Pulangan Atas Aset (ROA TTM) | 11.89% |
| Pulangan Atas Ekuiti (ROE TTM) | 18.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | United Therapeutics Corporation | Menaik | Menaik |
AISkor Stockmoo
-0.2
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.20 |
|
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.84% |
| % Dimiliki oleh Institusi | 99.97% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 600.00 (Oppenheimer, 73.87%) | Beli |
| Median | 400.00 (15.91%) | |
| Rendah | 302.00 (Goldman Sachs, -12.49%) | Pegang |
| Purata | 420.86 (21.96%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 372.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 08 Jan 2025 | 475.00 (37.65%) | Beli | 366.61 |
| Goldman Sachs | 01 Nov 2024 | 302.00 (-12.49%) | Pegang | 374.02 |
| Argus Research | 31 Oct 2024 | 400.00 (15.91%) | Beli | 373.97 |
| HC Wainwright & Co. | 31 Oct 2024 | 425.00 (23.16%) | Beli | 373.97 |
| Ladenburg Thalmann | 31 Oct 2024 | 344.00 (-0.31%) | Beli | 373.97 |
| Oppenheimer | 31 Oct 2024 | 600.00 (73.87%) | Beli | 373.97 |
| TD Cowen | 21 Oct 2024 | 400.00 (15.91%) | Beli | 370.60 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | - | 355.39 | -10,000 | -3,553,900 |
| MAHON PAUL A | - | 360.22 | -7,700 | -2,773,694 |
| Jumlah Keseluruhan Kuantiti Bersih | -17,700 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,327,594 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 357.81 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | Pegawai | 06 Jan 2025 | Jual automatik (-) | 10,000 | 355.39 | 3,553,900 |
| BENKOWITZ MICHAEL | Pegawai | 06 Jan 2025 | Pelaksanaan pilihan | 10,000 | - | - |
| MAHON PAUL A | Pegawai | 02 Jan 2025 | Jual automatik (-) | 7,700 | 360.22 | 2,773,694 |
| MAHON PAUL A | Pegawai | 02 Jan 2025 | Pelaksanaan pilihan | 7,700 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2025 | Pengumuman | United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2024 | Pengumuman | United Therapeutics Announces Successful World’s First UKidney Transplant |
| 05 Nov 2024 | Pengumuman | United Therapeutics Corporation to Present at the UBS Global Healthcare Conference |
| 30 Oct 2024 | Pengumuman | United Therapeutics Corporation Reports Third Quarter 2024 Financial Results |
| 23 Oct 2024 | Pengumuman | United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service |
| 23 Oct 2024 | Pengumuman | United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |